$CRDF
Cardiff Oncology, Inc. Stock $crdf

$crdf Overview Financials Valuation SEC Filings Company Website

2020 Form 10-K Financial Statement

#000162828021003277 Filed on February 25, 2021

Income Statement

Concept	2020	2019 Q4	2019
Revenue	$366.0K	$90.00K	$244.6K
YoY Change	49.61%	12.5%	-35.34%
Cost Of Revenue		$0.00	$0.00
YoY Change			-100.0%
Gross Profit		$90.00K	$244.6K
YoY Change		12.5%	-211.64%
Gross Profit Margin		100.0%	100.0%
Selling, General & Admin	$8.217M	$1.520M	$5.761M
YoY Change	42.63%	-9.52%	-28.04%
% of Gross Profit		1688.89%	2354.92%
Research & Development	$11.24M	$2.860M	$11.16M
YoY Change	0.66%	14.4%	36.72%
% of Gross Profit		3177.78%	4562.87%
Depreciation & Amortization	$466.0K	$360.0K	$494.2K
YoY Change	-5.71%	125.0%	-42.5%
% of Gross Profit		400.0%	202.03%
Operating Expenses	$19.45M	$4.380M	$16.92M
YoY Change	14.94%	4.78%	-2.92%
Operating Profit	-$19.09M	-$4.290M	-$16.68M
YoY Change	14.43%	4.63%	-2.2%
Interest Expense	$2.000K	$50.00K	$0.00
YoY Change		-54.55%	-100.0%
% of Operating Profit
Other Income/Expense, Net	-$221.0K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Pretax Income	-$19.31M	-$4.240M	-$16.41M
YoY Change	17.67%	1.92%	-0.3%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$19.31M	-$4.240M	-$16.41M
YoY Change	17.62%	1.92%	-0.29%
Net Earnings / Revenue	-5275.24%	-4711.11%	-6709.74%
Basic Earnings Per Share	-$1.08
Diluted Earnings Per Share	-$1.08	-$485.7K	-$2.749M
COMMON SHARES
Basic Shares Outstanding	20.88M shares	7.742M shares	5.974M shares
Diluted Shares Outstanding	20.88M shares

Balance Sheet

Concept	2020	2019 Q4	2019
SHORT-TERM ASSETS
Cash & Short-Term Investments	$131.0M	$10.20M	$10.20M
YoY Change	1184.31%	-11.3%	-11.3%
Cash & Equivalents	$131.0M	$10.20M	$10.20M
Short-Term Investments
Other Short-Term Assets	$2.100M	$1.000M	$1.000M
YoY Change	110.0%	-9.09%	-9.09%
Inventory
Prepaid Expenses		$955.0K
Receivables	$300.0K	$203.5K	$200.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$133.4M	$11.35M	$11.40M
YoY Change	1070.18%	-11.06%	-10.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.000M	$877.8K	$1.600M
YoY Change	-37.5%	-32.7%	23.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$400.0K	$157.6K	$200.0K
YoY Change	100.0%	53.29%	100.0%
Total Long-Term Assets	$1.300M	$1.733M	$1.700M
YoY Change	-23.53%	23.14%	21.43%
TOTAL ASSETS
Total Short-Term Assets	$133.4M	$11.35M	$11.40M
Total Long-Term Assets	$1.300M	$1.733M	$1.700M
Total Assets	$134.7M	$13.09M	$13.10M
YoY Change	928.24%	-7.66%	-7.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.400M	$656.3K	$700.0K
YoY Change	100.0%	-1.28%	0.0%
Accrued Expenses	$4.200M	$3.260M	$3.700M
YoY Change	13.51%	83.99%	164.29%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.100M	$4.782M	$4.800M
YoY Change	27.08%	63.57%	65.52%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$500.0K	$128.4K	$1.000M
YoY Change	-50.0%	205.64%	-16.67%
Total Long-Term Liabilities	$500.0K	$128.4K	$1.000M
YoY Change	-50.0%	205.64%	-16.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.100M	$4.782M	$4.800M
Total Long-Term Liabilities	$500.0K	$128.4K	$1.000M
Total Liabilities	$6.600M	$5.775M	$5.800M
YoY Change	13.79%	41.26%	41.46%
SHAREHOLDERS EQUITY
Retained Earnings		-$208.9M
YoY Change		8.69%
Common Stock		$8.312K
YoY Change		7.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$128.2M	$7.312M	$7.300M
YoY Change
Total Liabilities & Shareholders Equity	$134.7M	$13.09M	$13.10M
YoY Change	928.24%	-7.66%	-7.75%

Cashflow Statement

Concept	2020	2019 Q4	2019
OPERATING ACTIVITIES
Net Income	-$19.31M	-$4.240M	-$16.41M
YoY Change	17.62%	1.92%	-0.29%
Depreciation, Depletion And Amortization	$466.0K	$360.0K	$494.2K
YoY Change	-5.71%	125.0%	-42.5%
Cash From Operating Activities	-$16.32M	-$3.280M	-$13.27M
YoY Change	22.97%	-9.14%	0.52%
INVESTING ACTIVITIES
Capital Expenditures	$211.0K	$0.00	$67.62K
YoY Change	212.03%		1225.92%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$211.0K	$0.00	-$67.62K
YoY Change	212.03%		-396.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$112.3M		$8.818M
YoY Change	1173.56%		-25.14%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$137.3M	4.440M	$12.08M
YoY Change	1036.94%		-26.37%
NET CHANGE
Cash From Operating Activities	-$16.32M	-3.280M	-$13.27M
Cash From Investing Activities	-$211.0K	0.000	-$67.62K
Cash From Financing Activities	$137.3M	4.440M	$12.08M
Net Change In Cash	$120.8M	1.160M	-$1.258M
YoY Change	-9702.64%	-132.13%	-138.97%
FREE CASH FLOW
Cash From Operating Activities	-$16.32M	-$3.280M	-$13.27M
Capital Expenditures	$211.0K	$0.00	$67.62K
Free Cash Flow	-$16.53M	-$3.280M	-$13.34M
YoY Change	23.93%	-9.14%	0.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001213037
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-35558
CY2020	dei	Entity Registrant Name EntityRegistrantName	CARDIFF ONCOLOGY, INC.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-2004382
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	11055 Flintkote Avenue
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2020	dei	City Area Code CityAreaCode	858
CY2020	dei	Local Phone Number LocalPhoneNumber	952-7570
CY2020	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	103720151	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37052129	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	130980681	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10195292	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	320458	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	203480	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2055321	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	954957	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	133356460	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	11353729	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	623694	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	877823	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	343001	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	697418	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	404232	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	157576	USD
CY2020Q4	us-gaap	Assets Assets	134727387	USD
CY2019Q4	us-gaap	Assets Assets	13086546	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1366008	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	656304	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3850763	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3260061	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	860206	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	865379	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	42000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6118977	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	60	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4781744	USD
CY2020Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	284971	USD
CY2019Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	4127	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9291	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	860963	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	156266	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	128368	USD
CY2020Q4	us-gaap	Liabilities Liabilities	6569505	USD
CY2019Q4	us-gaap	Liabilities Liabilities	5775202	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	716	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36780805	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36780805	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8593633	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8593633	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	3678	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	8312	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	361820025	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	217172528	USD
CY2020Q4	trov	Servicereceivable Servicereceivable	2171258	USD
CY2019Q4	trov	Servicereceivable Servicereceivable	971673	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-231495279	USD
CY2020	us-gaap	Revenues Revenues	365993	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-208897883	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	128157882	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	7311344	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	134727387	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13086546	USD
CY2019	us-gaap	Revenues Revenues	244632	USD
CY2020	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	11235396	USD
CY2019	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	11162236	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8216471	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5760890	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	19451867	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	16923126	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-19085874	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-16678494	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	89809	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	234169	USD
CY2020	us-gaap	Interest Expense InterestExpense	1519	USD
CY2019	us-gaap	Interest Expense InterestExpense	0	USD
CY2020	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-28244	USD
CY2019	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	1978	USD
CY2020	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-280844	USD
CY2019	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	28188	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-19306672	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-16414159	USD
CY2020	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	24240	USD
CY2019	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	24240	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22597396	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16706668	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.08
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.80
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20874665	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5973906	shares
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	10084192	USD
CY2019	trov	Sale Of Stock Value Common And Warrants Net SaleOfStockValueCommonAndWarrantsNet	-8817772	USD
CY2019	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-40000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	884942	USD
CY2019	trov	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	3299510	USD
CY2019	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2019	trov	Beneficial Conversion Feature For Issuance Of Convertible Preferred Stock BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock	0	USD
CY2019	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2019	us-gaap	Dividends Preferred Stock DividendsPreferredStock	24240	USD
CY2019	trov	Release Of Clinical Trial Funding Commitment ReleaseOfClinicalTrialFundingCommitment	703327	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-16414159	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	7311344	USD
CY2020	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	112299949	USD
CY2020	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-7500	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1764804	USD
CY2020	trov	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	24871586	USD
CY2020	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2020	us-gaap	Dividends Preferred Stock DividendsPreferredStock	24240	USD
CY2020	trov	Release Of Clinical Trial Funding Commitment ReleaseOfClinicalTrialFundingCommitment	1100415	USD
CY2020	trov	Adjustments To Additional Paid In Capital Common Stock Par Value Adjustment AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment	0	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	148196	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-19306672	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	128157882	USD
CY2020	trov	Costof Issuanceof Common Stock Preferred Stockand Warrantsfor Clinical Trial Funding Commitment CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment	7507123	USD
CY2020	trov	Warrants Fair Value WarrantsFairValue	370666	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-19306672	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-16414159	USD
CY2020	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	34169	USD
CY2019	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	0	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	466009	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	494232	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	1764804	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	884943	USD
CY2020	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-280844	USD
CY2019	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	28188	USD
CY2020	trov	Releaseofclinicaltrialfundingcommitmentforservicesreceived Releaseofclinicaltrialfundingcommitmentforservicesreceived	1100415	USD
CY2019	trov	Releaseofclinicaltrialfundingcommitmentforservicesreceived Releaseofclinicaltrialfundingcommitmentforservicesreceived	703327	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	246656	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	54778	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	116978	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	35725	USD
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1100364	USD
CY2019	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-115459	USD
CY2020	trov	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-320248	USD
CY2019	trov	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-302491	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1276166	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1455336	USD
CY2020	trov	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-856845	USD
CY2019	trov	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-776806	USD
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	69898	USD
CY2019	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	86368	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16314962	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13267500	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	211880	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	67622	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-211880	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-67622	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	112299949	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8817772	USD
CY2020	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-7500	USD
CY2019	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-40000	USD
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	24871586	USD
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3299509	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	148196	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	305000	USD
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2020	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	305000	USD
CY2019	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	137312231	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12077281	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	120785389	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1257841	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10195292	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11453133	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130980681	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10195292	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	800	USD
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	800	USD
CY2020	trov	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	24240	USD
CY2019	trov	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	24240	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	131000000.0	USD
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimates involve accrued clinical trial expenses and determining the assumptions made for stock-based compensation.</span></div>
CY2020Q4	trov	Accrued Clinical Trial Expenses AccruedClinicalTrialExpenses	1683195	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11235396	USD
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposit accounts at financial institutions that are in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash due to the financial position of the depository institution in which those deposits are held. The Company limits its exposure to credit loss by generally placing its cash in high credit quality financial institutions and investment in non FDIC insured money market funds denominated and payable in U.S. dollars. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity.</span></div>
CY2020	us-gaap	Revenue Performance Obligation Description Of Payment Terms RevenuePerformanceObligationDescriptionOfPaymentTerms	Payment terms and conditions vary by contracts, although terms generally include a requirement of payment within 30 to 45 days after invoice.
CY2019	us-gaap	Depreciation Depreciation	494232	USD
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9807474	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11617078	shares
CY2020	us-gaap	Depreciation Depreciation	466009	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3627719	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3482116	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3004025	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2604293	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	623694	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	877823	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1523321	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1003383	USD
CY2020Q4	trov	Accrued Preferred Stock Dividend AccruedPreferredStockDividend	389495	USD
CY2019Q4	trov	Accrued Preferred Stock Dividend AccruedPreferredStockDividend	365255	USD
CY2020Q4	trov	Accrued Clinical Trial AccruedClinicalTrial	1557134	USD
CY2019Q4	trov	Accrued Clinical Trial AccruedClinicalTrial	1504660	USD
CY2020Q4	trov	Accruedresearchagreements Accruedresearchagreements	66593	USD
CY2019Q4	trov	Accruedresearchagreements Accruedresearchagreements	181408	USD
CY2020Q4	trov	Accrueddirectorfees Accrueddirectorfees	92500	USD
CY2019Q4	trov	Accrueddirectorfees Accrueddirectorfees	67500	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	38180	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	21000	USD
CY2020Q4	trov	Patentlicenseandotherfeespayable Patentlicenseandotherfeespayable	117440	USD
CY2019Q4	trov	Patentlicenseandotherfeespayable Patentlicenseandotherfeespayable	69950	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	66100	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	46905	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3850763	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3260061	USD
CY2020	trov	Lessee Operating Lease Monthly Rent Payment LesseeOperatingLeaseMonthlyRentPayment	78000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	343001	USD
CY2020	trov	Lessee Operating Lease Annual Rent Increase Percentage LesseeOperatingLeaseAnnualRentIncreasePercentage	0.03
CY2020	trov	Lessor Number Of Subleases LessorNumberOfSubleases	3
CY2020	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	34169	USD
CY2019	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	441529	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	444878	USD
CY2020	us-gaap	Sublease Income SubleaseIncome	291173	USD
CY2019	us-gaap	Sublease Income SubleaseIncome	381653	USD
CY2020	us-gaap	Lease Cost LeaseCost	150356	USD
CY2019	us-gaap	Lease Cost LeaseCost	63225	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	697418	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	860206	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	865379	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9291	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	860963	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	869497	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1726342	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.065
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.065
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	943959	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	916762	USD
CY2018Q4	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	8.91
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	889586	USD
CY2020Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	403345	USD
CY2020Q4	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths	486241	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5868	USD
CY2020Q4	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	0	USD
CY2020Q4	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Two LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo	5868	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3423	USD
CY2020Q4	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	0	USD
CY2020Q4	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Three LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree	3423	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	898877	USD
CY2020Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	403345	USD
CY2020Q4	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Due LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue	495532	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	29380	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	869497	USD
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3649341	shares
CY2018	trov	Warrants Weighted Average Contractual Term WarrantsWeightedAverageContractualTerm	P4Y4M24D
CY2019	trov	Class Of Warrant Or Right Number Granted ClassOfWarrantOrRightNumberGranted	7437454	shares
CY2019Q4	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	4.08
CY2019	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Granted ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted	1.87
CY2019	trov	Class Of Warrant Or Right Number Exercised ClassOfWarrantOrRightNumberExercised	497313	shares
CY2019	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised	6.60
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10589482	shares
CY2019	trov	Warrants Weighted Average Contractual Term WarrantsWeightedAverageContractualTerm	P3Y8M12D
CY2020	trov	Class Of Warrant Or Right Number Granted ClassOfWarrantOrRightNumberGranted	5831451	shares
CY2020	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Granted ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted	1.70
CY2020	trov	Class Of Warrant Or Right Number Exercised ClassOfWarrantOrRightNumberExercised	11159941	shares
CY2020	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised	2.31
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5260992	shares
CY2020Q4	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	5.19
CY2020	trov	Warrants Weighted Average Contractual Term WarrantsWeightedAverageContractualTerm	P4Y1M6D
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2019Q2	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	333333	shares
CY2019Q1	trov	Servicereceivable Servicereceivable	1675000	USD
CY2020Q2	trov	Class Of Warrant Or Right Months Until Exercisable ClassOfWarrantOrRightMonthsUntilExercisable	P6M
CY2020Q2	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	1546700	shares
CY2020Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2213115	shares
CY2020Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	863852	shares
CY2020Q2	trov	Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock	2700000	USD
CY2020Q2	trov	Class Of Warrant Or Right Issued ClassOfWarrantOrRightIssued	184426	shares
CY2020Q2	trov	Class Of Warrant Or Right Months Until Exercisable ClassOfWarrantOrRightMonthsUntilExercisable	P6M
CY2020Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.05
CY2020Q2	trov	Class Of Warrant Or Right Expiration Term ClassOfWarrantOrRightExpirationTerm	P5Y6M
CY2020Q2	trov	Warrants Fair Value WarrantsFairValue	370666	USD
CY2020Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	800000	shares
CY2020Q1	trov	Sale Of Stock Consideration Received On Transaction Gross SaleOfStockConsiderationReceivedOnTransactionGross	1000000.0	USD
CY2020Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	904970	shares
CY2020Q2	trov	Sale Of Stock Consideration Received On Transaction Gross SaleOfStockConsiderationReceivedOnTransactionGross	1100000	USD
CY2020Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	447761	shares
CY2020Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1.34
CY2020Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	146854	shares
CY2020Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1.43
CY2020Q2	trov	Sale Of Stock Consideration Received On Transaction Gross SaleOfStockConsiderationReceivedOnTransactionGross	810000	USD
CY2020Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1205400	shares
CY2020Q2	trov	Sale Of Stock Consideration Received On Transaction Gross SaleOfStockConsiderationReceivedOnTransactionGross	2500000	USD
CY2020Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	6500000	shares
CY2020Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	13.50
CY2020Q4	trov	Sale Of Stock Consideration Received On Transaction Gross SaleOfStockConsiderationReceivedOnTransactionGross	100900000	USD
CY2020Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	94000000.0	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1764804	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	884943	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1522984	USD
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	386654	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-4043000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2634000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-92000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-148000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4135000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2782000	USD
CY2020Q4	trov	Valuation Allowance ValuationAllowance	4134000	USD
CY2019Q4	trov	Valuation Allowance ValuationAllowance	2781000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4054000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3447000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-122000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.01
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-177000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.01
CY2020	trov	Income Tax Reconciliation Permanent Items IncomeTaxReconciliationPermanentItems	261000	USD
CY2020	trov	Effective Income Tax Rate Reconciliation Permanent Items EffectiveIncomeTaxRateReconciliationPermanentItems	-0.01
CY2019	trov	Income Tax Reconciliation Permanent Items IncomeTaxReconciliationPermanentItems	353000	USD
CY2019	trov	Effective Income Tax Rate Reconciliation Permanent Items EffectiveIncomeTaxRateReconciliationPermanentItems	-0.02
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	81000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.01
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	875000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.05
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	300000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.02
CY2019	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	384000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.02
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4134000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.22
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2780000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.17
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	42331000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	38494000	USD
CY2020Q4	trov	Deferred Tax Assets Tax Credit Carryforwards Research And Other DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther	3904000	USD
CY2019Q4	trov	Deferred Tax Assets Tax Credit Carryforwards Research And Other DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther	3710000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	684000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	531000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1116000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1252000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	48035000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	43987000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	74000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	154000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	6000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	12000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	80000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	166000	USD
CY2020Q4	trov	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	47955000	USD
CY2019Q4	trov	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	43821000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	47955000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	43821000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD

Files In Submission

Name	View Source	Status
0001628280-21-003277-index-headers.html	Edgar Link	pending
0001628280-21-003277-index.html	Edgar Link	pending
0001628280-21-003277.txt	Edgar Link	pending
0001628280-21-003277-xbrl.zip	Edgar Link	pending
a1016ex022521.htm	Edgar Link	pending
a1017ex022321.htm	Edgar Link	pending
a109ex022521.htm	Edgar Link	pending
a231exq42020.htm	Edgar Link	pending
a311exq42020.htm	Edgar Link	pending
a312exq42020.htm	Edgar Link	pending
a321exq42020.htm	Edgar Link	pending
a322exq42020.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
trov-20201231.htm	Edgar Link	pending
trov-20201231.xsd	Edgar Link	pending
trov-20201231_cal.xml	Edgar Link	unprocessable
trov-20201231_def.xml	Edgar Link	unprocessable
trov-20201231_htm.xml	Edgar Link	completed
trov-20201231_lab.xml	Edgar Link	unprocessable
trov-20201231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRDF
Cardiff Oncology, Inc. Stock $crdf

2020 Form 10-K Financial Statement

#000162828021003277 Filed on February 25, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF Cardiff Oncology, Inc. Stock $crdf

2020 Form 10-K Financial Statement

#000162828021003277 Filed on February 25, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF
Cardiff Oncology, Inc. Stock $crdf